An AI-powered voice-biomarker solution for early detection and severity assessment of heart failure.
The platform delivers non-invasive, highly accurate results (>95%)
in under 1 minute, enabling scalable deployment across hospitals, insurers, and consumer health markets.
Tablet PC with H2V app (fixed/portable) : non-invasive, voice input (~10 seconds) → results in <1 min
Target : 27K sites (primary, LTC, public), elderly (70+, chronic conditions, limited mobility)
Revenue Model : Monthly base fee $8~16/site and
Test Fee $4~8/each visit (inpatients once weekly)
Web/Mobile + AI speaker(voice) & smartwatch (ECG/HR)
Home-based HF risk management : 1-2 times per week, weekly reports, caregiver alerts
Revenue Model : $25-40/user/month
(B2B2C, bundled with facility fees)
Insurance benefits, local government programs,
NT-proBNP diagnostic partners
PoCs with Lotte E&C/Hotels, target launch in H2 2026
Growth Levers : premium discounts, B2B contracts, funded pilots
Sensitivity 71-82% (up to 3 weeks before Emergency)
AUC 91.9% (Consistency with Echo)
From early screening → diagnostic support → continuous monitoring
9 heart failure clinical parameters, 4-level severity prediction
Advanced Mel spectrogram preprocessing, CNN/Transformer-based deep-learning models.
Current: AUC ≥ 0.90, best-in-class among voice-based HF AI models to date
Non-invasive, ~10-seconds voice input → results in <1 min
Deployable as standalone or modular solution, no ECG
integration required
Medical : hospitals, long-term care facilities, public health centers
Non-medical : insurers, telecom operators, smartphones, senior care services
